Ipamorelin + CJC 5mg each

This combined peptide pack features Ipamorelin, a selective growth hormone secretagogue promoting musculoskeletal growth and repair, and CJC-1295, which increases natural growth hormone and IGF-1 levels with prolonged effects. Together, they support muscle development, fat loss, and enhanced recovery. Maximize your anabolic potential with this powerful duo—order today for accelerated fitness gains!

This combination includes two peptides:

• Ipamorelin (5mg x 5 vials): A selective growth hormone secretagogue that stimulates the release of growth hormone without affecting other hormonal pathways.
• Mod GRF (1-29) (CJC-1295 no DAC) (5mg x 5 vials): A modified version of growth hormone-releasing hormone that enhances the release of growth hormone by stimulating the pituitary gland.

Together, these peptides work synergistically to promote the natural secretion of growth hormone, supporting various physiological functions.

Ipamorelin Research

Mitigating Negative Effects of Glucocorticoids

Glucocorticoids are widely used to reduce inflammation in conditions such as cancer and autoimmune diseases but often cause serious side effects that limit their long-term use. Ipamorelin has demonstrated the ability to reduce or reverse many glucocorticoid-induced side effects, potentially allowing for higher dosing and extended treatment durations, which could improve patient outcomes.

Bone Health Benefits

One major complication of prolonged glucocorticoid use is bone density loss, increasing fracture risk. Current treatments, including bisphosphonates and hormone therapies, have limitations such as side effects and cost. Ipamorelin, however, is relatively inexpensive and well-tolerated, with studies in rats showing it can completely prevent corticosteroid-induced bone loss and even quadruple bone formation. It also enhances bone mineral density, strengthening both existing and new bone. Additionally, ipamorelin counters other steroid side effects like muscle wasting and increased visceral fat.

Muscle Growth and Preservation

Growth hormone (GH) secretagogues like ipamorelin may reduce glucocorticoid-related muscle catabolism. In glucocorticoid-treated rats, ipamorelin improved nitrogen balance and reduced muscle wasting—a frequent limiting factor in steroid therapy. Combining muscle and bone protective effects in a single compound could significantly benefit patients dependent on glucocorticoids.

Effects on Diabetes

Research in diabetic rats indicates ipamorelin can stimulate insulin release, likely by indirectly activating calcium channels on pancreatic islet cells. This effect could help elucidate functional impairments in type 2 diabetes and lead to novel treatments or preventive strategies.

Post-Operative Ileus (POI) Treatment

POI is a common complication after abdominal surgery characterized by temporary gastrointestinal paralysis, delaying oral intake and hospital discharge. Clinical trials exploring ipamorelin’s ability to shorten POI recovery showed a reduction in time to first meal by about 12 hours. Despite initial promise, development was halted due to insufficient efficacy. Ongoing research aims to enhance effectiveness, possibly via combination therapies.

Ghrelin Receptor Imaging Probe

Ipamorelin is a selective agonist of the ghrelin receptor, which is upregulated in certain cancers and heart failure. Preliminary in vitro studies suggest ipamorelin could be used as a positron emission tomography (PET) imaging probe to aid diagnosis. Further in vivo testing and standardization are needed to validate this application.

Research Potential and Future Directions

Although ipamorelin lacks orphan drug status and research interest waned after POI trials ceased, its multifaceted benefits and potential as a research tool keep it relevant. Renewed investigation with new data may revive its scientific and therapeutic prospects.

Research Applications

The combination of Ipamorelin and Mod GRF (1-29) is primarily utilized in scientific studies focusing on:

• Muscle Growth: Investigating their potential to increase lean muscle mass.
• Fat Reduction: Exploring their effects on reducing body fat.
• Bone Density: Assessing their role in enhancing bone strength and density.
• Cognitive Function: Studying their impact on memory and cognitive performance.
• Sleep Quality: Evaluating their influence on improving sleep patterns and quality.

These applications are part of ongoing research aimed at understanding the broader implications of this peptide combination in various biological processes.

References

• Raun KR et al., “Ipamorelin, the first selective growth hormone secretagogue,” Eur J Endocrinol, 1998;139(5):552-561. 
• Andersen NB et al., “Ipamorelin counteracts glucocorticoid-induced bone formation decrease in rats,” Growth Horm IGF Res, 2001;11(5):266-272. 
• Svensson J et al., “Ipamorelin increases bone mineral content in female rats,” J Endocrinol, 2000;165(3):569-577. 
• Aagaard NK et al., “GH secretagogue effects on nitrogen balance in steroid-treated rats,” Growth Horm IGF Res, 2009;19(5):426-431. 
• Adeghate E, Ponery AS., “Mechanism of ipamorelin-evoked insulin release in rats,” Neuro Endocrinol Lett, 2004;25(6):403-406. 
• Beck DE et al., “Proof-of-concept study of ipamorelin for postoperative ileus,” Int J Colorectal Dis, 2014;29(12):1527-1534. 
• Greenwood-Van Meerveld B et al., “Ipamorelin efficacy on gastric dysmotility,” J Exp Pharmacol, 2012;4:143-155. 
• Fowkes MM et al., “Growth hormone secretagogue derivatives for PET imaging of the ghrelin receptor,” Eur J Med Chem, 2018;157:1500-1511.